<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084847</url>
  </required_header>
  <id_info>
    <org_study_id>895</org_study_id>
    <nct_id>NCT04084847</nct_id>
  </id_info>
  <brief_title>Berberis Vulgaris Consumption and Blood Pressure</brief_title>
  <official_title>Effect of Berberis Vulgaris Consumption on Blood Pressure and Plasma Lipids in Subjects With Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of barberry consumption on systolic and
      diastolic blood pressure, serum lipids, and inflammatory status. The study will involve cases
      having elevated BP (129/ &lt; 85) and known hypertensive patients on medical treatment. Seventy
      people will be randomized into two groups, including intervention (barberry) or placebo
      groups.

      Before and after of 8 week intervention, 24-hour ambulatory blood pressure monitoring will be
      done and fasting venous blood sample will be taken to measure plasma lipids. In addition,
      24-hour urine will be collected to measure its sodium content and estimate sodium intake.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>mean of systolic and diastolic blood pressure of participants measured by ambulatory 24 hour blood pressure monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>plasma TC, LDL-C, HDL-C, TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma NOx</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>concentration of nitrite and nitrate in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokine</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>Plasma Interleukin-6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Lipid Profile</condition>
  <arm_group>
    <arm_group_label>Barberry</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily consumption of barberry in powder form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily consumption of placebo powder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>berberis vulgaris=barberry</intervention_name>
    <description>10 grams of barberry powder will be consumed daily for 8 weeks.</description>
    <arm_group_label>Barberry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo powder</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  willingness to participate in the study

          -  age between 20-65 years

          -  having elevated BP (129/ &lt; 85) and known hypertensive patients on medical treatment

          -  at least one other classical cardiovascular disease risk factors, including
             hyperlipidemia or diabetes mellitus

        Exclusion Criteria:

          -  Unwillingness to continue participation

          -  BMI&gt; 30

          -  patients on nitrates

          -  high doses of statins consumption (Atorvastatin&gt;40 mg/day or Rosuvastatin&gt;20 mg/day)

          -  consumption of vitamins or minerals supplements during past month

          -  Chronic kidney disease stage 4 or 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajaei Cardiovascular, Medical &amp; Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadi Emamat</last_name>
      <phone>+989132609664</phone>
      <email>hadiemamat@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>April 11, 2020</last_update_submitted>
  <last_update_submitted_qc>April 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Javad Nasrollahzadeh</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Barberry</keyword>
  <keyword>Berberis vulgaris</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Lipids</keyword>
  <keyword>Inflammation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

